{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T02:54:45Z","timestamp":1785034485134,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010349","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T00:00:00Z","timestamp":1492732800000}}],"reference-count":102,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010349.pub2","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T10:56:26Z","timestamp":1492772186000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma"],"prefix":"10.1002","volume":"2017","author":[{"given":"Kathelijne CJM","family":"Kraal","sequence":"first","affiliation":[{"name":"Emma Children's Hospital\/Academic Medical Center; Department of Paediatric Oncology; PO Box 22660 Amsterdam Netherlands 1100 DD"},{"name":"Princess Maxima Center for Pediatric Oncology; Postbus 85090 Room KE 01.129.2 Utrecht Netherlands 3508 AB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira C","family":"van Dalen","sequence":"additional","affiliation":[{"name":"Emma Children's Hospital\/Academic Medical Center; Department of Paediatric Oncology; PO Box 22660 Amsterdam Netherlands 1100 DD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godelieve AM","family":"Tytgat","sequence":"additional","affiliation":[{"name":"Emma Children's Hospital\/Academic Medical Center; Department of Paediatric Oncology; PO Box 22660 Amsterdam Netherlands 1100 DD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthe LF","family":"Van Eck-Smit","sequence":"additional","affiliation":[{"name":"Academic Medical Center; Nuclear Medicine; P.O Box 9 Amsterdam Netherlands 2200 DD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,21]]},"reference":[{"key":"10.1002\/14651858.CD010349.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ejca.2008.01.010","article-title":"Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age","volume":"44","author":"Kraker","year":"2008","journal-title":"European Journal of Cancer"},{"issue":"11","key":"10.1002\/14651858.CD010349.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/pbc.25580","article-title":"Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan","volume":"62","author":"Kraal","year":"2015","journal-title":"Pediatric Blood and Cancer"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0003|cit3","unstructured":"Bleeker G Schoot R Caron H van Eck B de Kraker J Tytgat G 20 years of 131iodine-metaiodobenzylguanidine (131I-MIBG) therapy upfront: a retrospective analysis of acute toxicity Pediatric Blood and Cancer 2009 736"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00259-013-2510-z","article-title":"Toxicity of upfront 131I-meta-iodobenzylguanidine (131I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis","volume":"40","author":"Bleeker","year":"2013","journal-title":"European Journal of Nuclear Medical Molecular Imaging"},{"issue":"1","key":"10.1002\/14651858.CD010349.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/mpo.1261","article-title":"Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking","volume":"38","author":"Brans","year":"2002","journal-title":"Medical and Pediatric Oncology"},{"issue":"1","key":"10.1002\/14651858.CD010349.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00003072-198901000-00006","article-title":"Radionuclide therapy of pheochromocytomas and neuroblastomas using iodine-131 metaiodobenzylguanidine (MIBG)","volume":"14","author":"Brendel","year":"1989","journal-title":"Clinical Nuclear Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010349.pub2-BIB0007|cit7","first-page":"1","article-title":"Diagnostic and therapeutic use of 131I-metaiodobenzylguanidine in children with neuroblastoma","volume":"32","author":"Claudiani","year":"1988","journal-title":"Journal of Nuclear Medicine and Allied Sciences"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/pbc.24681","article-title":"Long term follow-up of the thyroid gland after treatment with 131I-metaiodobenzylguanidine in children with neuroblastoma: importance of continuous surveillance","volume":"60","author":"Clement","year":"2013","journal-title":"Pediatric Blood and Cancer"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00259-014-2967-4","article-title":"Long term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during 131I-metaiodobenzylguanidine treatment in children with neuroblastoma","volume":"42","author":"Clement","year":"2015","journal-title":"European Journal of Medical Molecular Imaging"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0010|cit10","first-page":"228","article-title":"[131I]metaiodobenzylguanidine and high-dose chemotherapy with bone marrow rescue in advanced neuroblastoma","volume":"35","author":"Corbett","year":"1991","journal-title":"Journal of Nuclear Biology and Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010349.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/0959-8049(95)00063-O","article-title":"First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma","volume":"31A","author":"Kraker","year":"1995","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1055\/s-0038-1624337","article-title":"Diagnosis and treatment of neuroblastoma using 131I-meta-iodobenzylguanidine","volume":"25","author":"Edeling","year":"1986","journal-title":"Nuklearmedizin"},{"issue":"1","key":"10.1002\/14651858.CD010349.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4103\/2278-0513.110777","article-title":"Management of neuroblastoma. Comparative study between 1st and 2nd line radioionated MIBG therapy and chemotherapy alone","volume":"2","author":"El-Sabban","year":"2013","journal-title":"Clinical Cancer Investigation Journal"},{"issue":"4, Suppl 1","key":"10.1002\/14651858.CD010349.pub2-BIB0014|cit14","first-page":"58","article-title":"Place of meta-[131I]iodobenzylguanidine in the treatment of neuroblastoma: the Genoa experience","volume":"39","author":"Garaventa","year":"1995","journal-title":"Quarterly Journal of Nuclear Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010349.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/cncr.11167","article-title":"Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine","volume":"97","author":"Garaventa","year":"2003","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1259\/0007-1285-60-712-393","article-title":"Imaging and treatment of disseminated neuroblastoma with 131I-metaiodobenzylguanidine","volume":"60","author":"Gerrard","year":"1987","journal-title":"British Journal of Radiology"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0017|cit17","first-page":"655","article-title":"The therapeutic use of I-131 meta-iodobenzylguanidine (mIBG) in neuroblastoma: a phase II study in 12 patients","volume":"271","author":"Hartmann","year":"1988","journal-title":"Progressive Clinical Biological Research"},{"issue":"3","key":"10.1002\/14651858.CD010349.pub2-BIB0018|cit18","first-page":"308","article-title":"Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine","volume":"28","author":"Hoefnagel","year":"1987","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0019|cit19","first-page":"1367","article-title":"Diagnosis and therapy of neural crest tumors with 131I-meta-iodobenzylguanidine","volume":"132","author":"Hoefnagel","year":"1988","journal-title":"Nederlands Tijdschrift voor Geneeskunde"},{"issue":"4","key":"10.1002\/14651858.CD010349.pub2-BIB0020|cit20","first-page":"248","article-title":"Preoperative [131I]metaiodobenzylguanidine therapy of neuroblastoma at diagnosis (\"MIBG de novo\")","volume":"35","author":"Hoefnagel","year":"1991","journal-title":"Journal of Nuclear Biology and Medicine"},{"issue":"9","key":"10.1002\/14651858.CD010349.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/00006231-199409000-00008","article-title":"131I-MIBG as a first-line treatment in high-risk neuroblastoma patients","volume":"15","author":"Hoefnagel","year":"1994","journal-title":"Nuclear Medicine Communications"},{"issue":"4 (Suppl 1)","key":"10.1002\/14651858.CD010349.pub2-BIB0022|cit22","first-page":"61","article-title":"[131I]MIBG as a first line treatment in advanced neuroblastoma","volume":"39","author":"Hoefnagel","year":"1995","journal-title":"Quarterly Journal of Nuclear Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010349.pub2-BIB0023|cit23","first-page":"216","article-title":"Treatment of neuroblastoma with [131I]metaiodobenzylguanidine: long-term results in 25 patients","volume":"35","author":"Klingebiel","year":"1991","journal-title":"Journal of Nuclear Biology and Medicine"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0024|cit24","first-page":"309","article-title":"Peripheral stem cell transplantation in neuroblastoma stage 4 with the use of [131I-m]IBG","volume":"385","author":"Klingebiel","year":"1994","journal-title":"Progress in Clinical and Biological Research"},{"issue":"9","key":"10.1002\/14651858.CD010349.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S0959-8049(98)00130-0","article-title":"Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study","volume":"34","author":"Klingebiel","year":"1998","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD010349.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00259-011-2022-7","article-title":"Hypertension complicating 131I-metaiodobenzylguanidine therapy for neuroblastoma","volume":"39","author":"Kosmin","year":"2012","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"1","key":"10.1002\/14651858.CD010349.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/mpo.2950180107","article-title":"Systemic administration of radionuclides in neuroblastoma as planned radiotherapeutic intervention","volume":"18","author":"Lashford","year":"1990","journal-title":"Medical and Pediatric Oncology"},{"issue":"4","key":"10.1002\/14651858.CD010349.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mpo.2950150403","article-title":"The treatment of neuroblastoma with 131I-MIBG","volume":"15","author":"Mastrangelo","year":"1987","journal-title":"Medical and Pediatric Oncology"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0029|cit29","first-page":"252","article-title":"[131I]metaiodobenzylguanidine in neuroblastoma patients at diagnosis","volume":"35","author":"Mastrangelo","year":"1991","journal-title":"Journal of Nuclear Biology and Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010349.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1054\/bjoc.2000.1645","article-title":"Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy","volume":"84","author":"Mastrangelo","year":"2001","journal-title":"British Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD010349.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/pbc.22986","article-title":"Treatment of advanced neuroblastoma in children over 1 year of age: the critical role of 131I-metaiodobenzylguanidine therapy combined with chemotherapy in a rapid induction regimen","volume":"56","author":"Mastrangelo","year":"2011","journal-title":"Pediatric Blood & Cancer"},{"issue":"7","key":"10.1002\/14651858.CD010349.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2007.15.7628","article-title":"Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study","volume":"27","author":"Matthay","year":"2009","journal-title":"Journal Clinical Oncology"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0883-2889(86)90271-6","article-title":"Radioiodinated iodobenzylguanidines for diagnosis and therapy","volume":"37","author":"McEwan","year":"1986","journal-title":"Applied Radiation and Isotopes, Part A"},{"issue":"1","key":"10.1002\/14651858.CD010349.pub2-BIB0034|cit34","first-page":"7","article-title":"Therapeutic possibilities of (m-iodo(131I)benzyl)guanidine","volume":"8","author":"Mitjavila","year":"1989","journal-title":"Revista Espanola de Medicina Nuclear"},{"issue":"4","key":"10.1002\/14651858.CD010349.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00006231-200104000-00004","article-title":"Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours","volume":"22","author":"Monsieurs","year":"2001","journal-title":"Nuclear Medicine Communications"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0036|cit36","first-page":"510","article-title":"Radiometabolic diagnosis and treatment of neuroblastoma using 131I-MIBG: personal research","volume":"13","author":"Mussa","year":"1987","journal-title":"Rivista Italiana di Pediatria"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0037|cit37","first-page":"455","article-title":"Therapeutic implications of the uptake of radiolabelled mIBG for the treatment of neuroblastoma","volume":"366","author":"O'Donoghue","year":"1991","journal-title":"Progress in Clinical and Biological Research"},{"issue":"9","key":"10.1002\/14651858.CD010349.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/1097-0142(19951101)76:9<1662::AID-CNCR2820760924>3.0.CO;2-V","article-title":"Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma","volume":"76","author":"Picco","year":"1995","journal-title":"Cancer"},{"issue":"12","key":"10.1002\/14651858.CD010349.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/MNM.0b013e32834bad97","article-title":"131I Metaiodobenzylguanidine therapy in neural crest tumors: varying outcome in different histopathologies","volume":"32","author":"Rachh","year":"2011","journal-title":"Nuclear Medicine Communication"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0040|cit40","doi-asserted-by":"crossref","unstructured":"Schoot R Bleeker G Heij H van Eck B Caron H de Kraker J The role of 131I-metaiodobenzylguanidine (131i-MIBG) therapy in unresectable and compromising localized neuroblastoma Pediatric Blood and Cancer 2009 807 8","DOI":"10.1200\/jco.2009.27.15_suppl.10053"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Schoot RA Bleeker G Heij HA van Eck BL Caron HN de Kraker J The role of 131-I-metaiodobenzylguanidine (13II-MIBG) therapy in irresectable and compromising localized neuroblastoma Journal of Clinical Oncology 2009 10053","DOI":"10.1200\/jco.2009.27.15_suppl.10053"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0042|cit42","first-page":"357","article-title":"Summary, conclusions, and future directions of [131I]metaiodobenzylguanidine therapy in the treatment of neural crest tumors","volume":"35","author":"Shapiro","year":"1991","journal-title":"Journal of Nuclear Biology and Medicine"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00259-010-1391-7","article-title":"Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma","volume":"37","author":"Sudbrock","year":"2010","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0044|cit44","first-page":"101","article-title":"Iodine labelled meta-iodobenzyl guanidine (mIBG) in the localisation and treatment of malignant phaeochromocytoma and neuroblastoma","volume":"3","author":"Sutton","year":"1982","journal-title":"Nuclear Medicine Communications"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/bjc.2013.365","article-title":"Sequalae and survivorship in patients treated with 131I-MIBG therapy","volume":"109","author":"Sze","year":"2013","journal-title":"British Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD010349.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1089\/thy.2012.0149","article-title":"Differentiated thyroid carcinoma after iodine-131 metaiodobenzylguanidine treatment for neuroblastoma: assessment of causality","volume":"23","author":"Teszler","year":"2013","journal-title":"Thyroid"},{"issue":"3","key":"10.1002\/14651858.CD010349.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1055\/s-2008-1066495","article-title":"Pretreatment with [131I] metaiodobenzylguanidine and surgical resection of advanced neuroblastoma","volume":"6","author":"Hasselt","year":"1996","journal-title":"European Journal of Pediatric Surgery"},{"issue":"7","key":"10.1002\/14651858.CD010349.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/cncr.10447","article-title":"High in despite prophylaxis with potassium iodide during 131I-metaiodobenzylguanide treatment in children with neuroblastoma","volume":"94","author":"Santen","year":"2002","journal-title":"Cancer"},{"issue":"12","key":"10.1002\/14651858.CD010349.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.ejca.2005.02.036","article-title":"Endocrine late effects from multi-modality treatment of neuroblastoma","volume":"41","author":"Santen","year":"2005","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0050|cit50","unstructured":"Van Santen HM Clement S van Eck BLF Tytgat LA van Trotsenburg PASP Increasing incidence and severity of thyroid damage 15 years after 131I-metaiodobenzylguanidine treatment in children with neuroblastoma 94th Annual Meeting and Expo of the Endocrine Society; Jun 23-26; Houston (TX) 2012"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/pbc.24681","article-title":"Long-term follow-up of the thyroid gland after treatment with131I-metaiodobenzylguanidine in children with neuroblastoma: importance of continuous surveillance","volume":"60","author":"Clement","year":"2013","journal-title":"Pediatric Blood and Cancer"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0052|cit52","unstructured":"Vitale V Hanau G Caruso S Cabria M Piccardo A Altrinetti V Late toxicity after 131 I-MIBG therapy in children with neuroblastoma European Journal of Nuclear Medicine and Molecular Imaging 2012 S317"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0053|cit53","article-title":"Treatment of neuroblastoma (NBL) with 131I-metaiodobenzylguanidine (131I-MIBG)","volume":"26","author":"Voute","year":"1985","journal-title":"Proceedings of the American Association for Cancer Research"},{"issue":"4","key":"10.1002\/14651858.CD010349.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/mpo.2950150410","article-title":"Radionuclide therapy of neural crest tumors","volume":"15","author":"Voute","year":"1987","journal-title":"Medical and Pediatric Oncology"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0055|cit55","first-page":"107","article-title":"131I-meta-iodobenzylguanidine in diagnosis and treatment of neuroblastoma","volume":"94","author":"Voute","year":"1987","journal-title":"Gazette Medicale"},{"issue":"1","key":"10.1002\/14651858.CD010349.pub2-BIB0056|cit56","first-page":"107","article-title":"131I-meta-iodobenzylguanidine in diagnosis and treatment of neuroblastoma","volume":"75","author":"Voute","year":"1988","journal-title":"Bulletin du Cancer"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0057|cit57","first-page":"679","article-title":"Side effects of treatment with I-131-meta-iodobenzylguanidine (I-131-MIBG) in neuroblastoma patients","volume":"271","author":"Voute","year":"1988","journal-title":"Progress in Clinical and Biological Research"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0058|cit58","first-page":"439","article-title":"Results of treatment with 131 I-metaiodobenzylguanidine (131 I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy","volume":"366","author":"Voute","year":"1991","journal-title":"Progress in Clinical and Biological Research"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/pbc.24551","article-title":"Acute changes in blood pressure in patients with neuroblastoma treated with 131I-metaiodobenzylguanidine (MIBG)","volume":"60","author":"Wong","year":"2013","journal-title":"Pediatric Blood and Cancer"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0060|cit60","first-page":"S156","article-title":"A mean to optimize transplant regimen for neuroblastoma: the role of pre-transplant MIBG scintigraphy in targeted administration of 131I-MIBG accompanied by autologous stem cell transplantation","volume":"49","author":"Hamidieh","year":"2014","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0061|cit61","unstructured":"Kraal KCJM Bleeker GM de Kwaasteniet M van Eck-Smit BLF van Noesel MM Pilot feasibility and toxicity of 2 cycles of upfront 131I-MIBG Advances in Neuroblastoma Research 2012 Conference; Jun 18-21 2012; Toronto, Canada 2012"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0062|cit62","unstructured":"Leung WK Lee V Kam M Wai Tsoi Cheng F Shing MK Kong C Treatment outcome of high dose 131I-MIBG treatment in stage 4 neuroblastoma in Hong Kong 26th Annual SIOP Conference; 2011 Apr 14-16; Auckland, New Zealand 2011"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0063|cit63","unstructured":"Leung WK Lee V Kam MKM Cheung JSS Cheng FWT Shing MK High dose 131I-MIBG treatment in stage 4 neuroblastoma patients in a tertiary centre in Hong Kong 28th Annual SIOP Conference; 2011 Apr 11-13; Houston (TX) 2013"},{"issue":"3","key":"10.1002\/14651858.CD010349.pub2-BIB0064|cit64","first-page":"209","article-title":"Neuroblastoma: prognostic factors and survival. Experience in Hospital de Pediatria del Centro Medico Nacional del Siglo XXI and review of the literature","volume":"139","author":"L\u00f3pez-Aguilar","year":"2003","journal-title":"Gaceta Medico de Mexico"},{"issue":"4","key":"10.1002\/14651858.CD010349.pub2-BIB0065|cit65","first-page":"461","article-title":"131I-meta-iodobenzylguanidine (MIBG) for the detection and therapy of pheochromocytoma and neuroblastoma","volume":"32","author":"Nakajo","year":"1987","journal-title":"Rinsho Hoshasen"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0066|cit66","unstructured":"NCT01175356 Induction therapy including 131 I-MIBG and chemotherapy in treating patients with newly diagnosed high-risk neuroblastoma undergoing stem cell transplant, radiation therapy, and maintenance therapy with isotretinoin clinicaltrials.gov\/ct2\/show\/NCT01175356"},{"issue":"2","key":"10.1002\/14651858.CD010349.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1200\/JCO.1992.10.2.323","article-title":"A population-based study of neuroblastoma incidence, survival, and mortality in North America","volume":"10","author":"Bernstein","year":"1992","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD010349.pub2-BIB0068|cit68","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009263.pub2","article-title":"123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma","author":"Bleeker","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD010349.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","article-title":"Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment","volume":"11","author":"Brodeur","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010349.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report","volume":"27","author":"Cohn","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"9303","key":"10.1002\/14651858.CD010349.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(02)07500-1","article-title":"Cohort studies: marching towards outcomes","volume":"359","author":"Grimes","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD010349.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/(SICI)1097-0142(19960801)78:3<532::AID-CNCR22>3.0.CO;2-Z","article-title":"Trends in cancer incidence among children in the US","volume":"78","author":"Gurney","year":"1996","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD010349.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2214\/ajr.143.2.373","article-title":"Localization of m-iodo(131I)benzylguanidine in neuroblastoma","volume":"143","author":"Hattner","year":"1984","journal-title":"American Journal of Roentgenology"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0074|cit74","unstructured":"Higgins JPT Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD010349.pub2-BIB0075|cit75","first-page":"21","article-title":"Total-body scintigraphy with 131I-meta-iodobenzylguanidine for detection of neuroblastoma","volume":"54","author":"Hoefnagel","year":"1985","journal-title":"Diagnostic Imaging in Clinical Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010349.pub2-BIB0076|cit76","first-page":"237","article-title":"Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma","volume":"35","author":"Hutchinson","year":"1991","journal-title":"Journal of Nuclear Biology and Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010349.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/mpo.2950190203","article-title":"Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial","volume":"19","author":"Klingebiel","year":"1991","journal-title":"Medical and Pediatric Oncology"},{"issue":"4","key":"10.1002\/14651858.CD010349.pub2-BIB0078|cit78","first-page":"216","article-title":"Treatment of neuroblastoma with [131I]metaiodobenzylguanidine: long-term results in 25 patients","volume":"35","author":"Klingebiel","year":"1991","journal-title":"Journal of Nuclear Biology and Medicine"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0079|cit79","unstructured":"Kremer LCM van Dalen EC Moher D Caron HN Cochrane Childhood Cancer Group About The Cochrane Collaboration (Cochrane Review Groups (CRGSs))"},{"issue":"12","key":"10.1002\/14651858.CD010349.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.1992.10.12.1889","article-title":"Phase I\/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation","volume":"10","author":"Lashford","year":"1992","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD010349.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jama.1994.03520030076032","article-title":"Users' guides to the medical literature. V. How to use an article about prognosis","volume":"272","author":"Laupacis","year":"1994","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD010349.pub2-BIB0082|cit82","first-page":"1352","article-title":"Specificity of radioiodinated MIBG for neural crest tumors in childhood","volume":"38","author":"Leung","year":"1997","journal-title":"Journal of Nuclear Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010349.pub2-BIB0083|cit83","first-page":"220","article-title":"Therapeutic use of [131I]metaiodobenzylguanidine in neuroblastoma: a phase II study in 26 patients. \"Societe Francaise d'Oncologie Pediatrique\" and Nuclear Medicine Co-investigators","volume":"35","author":"Lumbroso","year":"1991","journal-title":"Journal of Nuclear Biology and Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010349.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.1998.16.1.229","article-title":"Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma","volume":"16","author":"Matthay","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1002\/14651858.CD010349.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","article-title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group","volume":"341","author":"Matthay","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD010349.pub2-BIB0086|cit86","first-page":"1713","article-title":"Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG","volume":"42","author":"Matthay","year":"2001","journal-title":"Journal of Nuclear Medicine"},{"issue":"9","key":"10.1002\/14651858.CD010349.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1200\/JCO.2006.09.3484","article-title":"Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma","volume":"25","author":"Matthay","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD010349.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2007.13.8925","article-title":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic Acid: a Children's Oncology Group Study","volume":"27","author":"Matthay","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"33","key":"10.1002\/14651858.CD010349.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1200\/JCO.2010.34.3293","article-title":"Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children\u2019s Oncology Group study","volume":"29","author":"Park","year":"2011","journal-title":"Journal Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD010349.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics Medical"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(08)70069-X","article-title":"High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial","volume":"3","author":"Pearson","year":"2008","journal-title":"Lancet Oncology"},{"issue":"5","key":"10.1002\/14651858.CD010349.pub2-BIB0092|cit92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010774.pub2","article-title":"Rapid COJEC versus standard induction therapies for high-risk neuroblastoma","author":"Peinemann","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010349.pub2-BIB0093|cit93","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010685.pub2","article-title":"Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation","author":"Peinemann","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2014.59.4648","article-title":"Advances in risk classification and treatment strategies for neuroblastoma","volume":"33","author":"Pinto","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010349.pub2-BIB0095|cit95","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"19","key":"10.1002\/14651858.CD010349.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/jnci\/87.19.1470","article-title":"Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis","volume":"87","author":"Shimada","year":"1995","journal-title":"Journal National Cancer Institute"},{"issue":"2","key":"10.1002\/14651858.CD010349.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.0.CO;2-7","article-title":"The International Neuroblastoma Pathology Classification (the Shimada system)","volume":"86","author":"Shimada","year":"1999","journal-title":"Cancer"},{"issue":"4","key":"10.1002\/14651858.CD010349.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/pbc.22693","article-title":"Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials","volume":"56","author":"Simon","year":"2011","journal-title":"Pediatric Blood and Cancer"},{"issue":"4","key":"10.1002\/14651858.CD010349.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/(SICI)1097-0142(19960215)77:4<805::AID-CNCR29>3.0.CO;2-3","article-title":"Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system","volume":"77","author":"Suc","year":"1996","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD010349.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/pbc.25816","article-title":"Impact of whole-body radiation dose on response and toxicity in patients with neuroblastoma after therapy with 131 I-metaiodobenzylguanidine (MIBG)","volume":"63","author":"Trieu","year":"2016","journal-title":"Pediatric Blood & Cancer"},{"issue":"10","key":"10.1002\/14651858.CD010349.pub2-BIB0101|cit101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006301.pub4","article-title":"High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma","author":"Yal\u00e7in","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD010349.pub2-BIB0102|cit102","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010349","article-title":"Iodine-131-meta-iodobenzylguanidine therapy for patients with high-risk neuroblastoma","author":"Kraal","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010349.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T13:50:38Z","timestamp":1626097838000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010349.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Childhood Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,4,21]]},"references-count":102,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010349.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,21]]}}}